TSAAI 2021 Annual Meeting

August 13, 2021 to August 15, 2021

It is an exciting time in the field of allergy and immunology!  This CME program is designed to allow attendees to continue exploring the Immunology Frontier.  Covered topics include current and emerging treatments in HAE, Peanut Immunotherapy, translational targets for new asthma therapeutics, and updates on immunodeficiencies.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Tennessee Society of Allergy, Asthma and Immunology. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Commercial Support
This activity is supported in part by a medical education grant from CSL Behring.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Recognize the mechanism of action o the different biologics available to treat severe asthma
  2. Describe when and how to initiate appropriate treatment with specific biologics 
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.


Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
Course expires: 
Event starts: 
08/13/2021 - 4:00pm CDT
Event ends: 
08/15/2021 - 11:30pm CDT

All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:

William Busse MD, speaker
Disclosures: Consultant: AstraZeneca, Novartis, Regeneron, Sanofi, GlaxoSmithKline, Genentech
Katherine Cahill, MD, speaker
Disclosures: Advisory Board Member: Novartis, Regeneron, Sanofi, Genentech
                      Consultant: Blueprint Medicines, Ribon Therapeutics 
Monica Lawrence, MD, speaker
Disclosures: Other/Principal Investigator: American Lung Association, Jeffrey Modell Foundation, AAAAI 
                       Consultant: X4 Pharmaceuticals, Horizon Therapeutics
                       Other/Loan repayment program participant: NIH 
Jay Lieberman, MD, speaker
Disclosures: Advisory Board Member: DBV Technologies, Novartis
                      Speaker: Novartis/Genentech
                      Other/Data Safety Monitoring Committee Board Member: Siolta Therapeutics
                      Other/Research: Aimmune Therapeutics, DBV Technologies, Regeneron, Novartis
                      Other/Editorial Board Member: Annals of Allergy, Asthma and Immunology
                      Other/Committee Member: JTFPP, ABAI Board, ACAAI Food Allergy Committee Chair
Marc Serota, MD, speaker
Disclosures: Consultant: Regeneron, Sanofi-Genzyme, Genentech, Novartis, Pfizer, Celgene, Amgen
Mike Tankersley, MD, speaker
Disclosures: Consultant: ALK
                       Advisory Board Member: ALK
The following have no relevant financial relationships to disclose:
Karthik Krishnan, MD, Program Chair and Physician Planner
Michelle Kittle, Meeting Coordinator

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.